254 related articles for article (PubMed ID: 21498008)
1. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.
Bekelman JE; Mitra N; Efstathiou J; Liao K; Sunderland R; Yeboa DN; Armstrong K
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e325-34. PubMed ID: 21498008
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
Sheets NC; Goldin GH; Meyer AM; Wu Y; Chang Y; Stürmer T; Holmes JA; Reeve BB; Godley PA; Carpenter WR; Chen RC
JAMA; 2012 Apr; 307(15):1611-20. PubMed ID: 22511689
[TBL] [Abstract][Full Text] [Related]
3. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
Sujenthiran A; Nossiter J; Charman SC; Parry M; Dasgupta P; van der Meulen J; Cathcart PJ; Clarke NW; Payne H; Aggarwal A
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1253-1260. PubMed ID: 28974414
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
5. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract][Full Text] [Related]
6. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.
Bruner DW; Hunt D; Michalski JM; Bosch WR; Galvin JM; Amin M; Xiao C; Bahary JP; Patel M; Chafe S; Rodrigues G; Lau H; Duclos M; Baikadi M; Deshmukh S; Sandler HM
Cancer; 2015 Jul; 121(14):2422-30. PubMed ID: 25847819
[TBL] [Abstract][Full Text] [Related]
7. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
Ashman JB; Zelefsky MJ; Hunt MS; Leibel SA; Fuks Z
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):765-71. PubMed ID: 15913914
[TBL] [Abstract][Full Text] [Related]
8. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
9. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.
Samuelian JM; Callister MD; Ashman JB; Young-Fadok TM; Borad MJ; Gunderson LL
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1981-7. PubMed ID: 21477938
[TBL] [Abstract][Full Text] [Related]
10. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Krenkel B; Eble MJ
Strahlenther Onkol; 2011 Aug; 187(8):479-84. PubMed ID: 21789739
[TBL] [Abstract][Full Text] [Related]
11. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
[TBL] [Abstract][Full Text] [Related]
12. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.
Goldin GH; Sheets NC; Meyer AM; Kuo TM; Wu Y; Stürmer T; Godley PA; Carpenter WR; Chen RC
JAMA Intern Med; 2013 Jun; 173(12):1136-43. PubMed ID: 23689844
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.
Crandley EF; Hegarty SE; Hyslop T; Wilson DD; Dicker AP; Showalter TN
Cancer Med; 2014 Apr; 3(2):397-405. PubMed ID: 24519910
[TBL] [Abstract][Full Text] [Related]
15. [A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor].
Ni J; Yin ZM; Yuan SH; Liu NF; Li L; Xu XX; Lou HM
Zhonghua Fu Chan Ke Za Zhi; 2017 Mar; 52(3):168-174. PubMed ID: 28355688
[No Abstract] [Full Text] [Related]
16. Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference?
Viani G; Hamamura AC; Faustino AC
Int Braz J Urol; 2019; 45(6):1105-1112. PubMed ID: 31808397
[TBL] [Abstract][Full Text] [Related]
17. Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study.
Sujenthiran A; Nossiter J; Parry M; Charman SC; Cathcart PJ; van der Meulen J; Clarke NW; Payne H; Aggarwal A
Radiother Oncol; 2018 Aug; 128(2):357-363. PubMed ID: 29773442
[TBL] [Abstract][Full Text] [Related]
18. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.
Löser A; Beyer B; Carl CO; Löser B; Nagaraj Y; Frenzel T; Petersen C; Krüll A; Graefen M; Schwarz R
Strahlenther Onkol; 2019 May; 195(5):374-382. PubMed ID: 30390115
[TBL] [Abstract][Full Text] [Related]
20. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer.
Lin SH; Zhang N; Godby J; Wang J; Marsh GD; Liao Z; Komaki R; Ho L; Hofstetter WL; Swisher SG; Mehran RJ; Buchholz TA; Elting LS; Giordano SH
Cancer; 2016 Mar; 122(6):917-28. PubMed ID: 26716915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
